Thiotepa versus Adriamycin versus Cis-Platinum in the Intravesical Prophylaxis of Superficial Bladder Tumors

Abstract

A study was performed on 184 patients with superficial bladder cancer (pTa, pT1), 92 with primary and 92 recurrent tumors. After TUR of all visible lesions, endovesical chemotherapy with thiotepa, adriamycin or cisplatinum was started on the 15th and 30th days following surgery. There were no statistically significant differences between any of the three chemotherapies at the doses and intervals mentioned. Only cis-platinum has proven to be more effective in primary high grade tumor.

Baltasar Llopis Mínguez (1934-1990). Pionero en la investigación del cáncer vesical y en la introducción de la informática en Urología

“…Una vez introducidas estas características del tumor de cada enfermo, el modelo matemático del programa resuelve y calcula la probabilidad relativa personalizada de aparición de nuevas neoplasias, posteriormente los clasifica en grupos de bajo, intermedio o alto grado de recaída y les asigna una determinada pauta de quimioterapia. Publica los resultados tras la aplicación de su protocolo de profilaxis orientada hacia el tratamiento con citostáticos locales [17][18][19][20][21][22] (fig. 5).…”

Global Problem of Drug‐Induced Hearing Loss

“…2 • 22 • 40 • 66 Intravescicular administration of cisplatin can be used in the treatment of superficial cancers of the bladder. 42 Cisplatin toxicity is legendary. Its major manifestation is cumulative, dose-dependent tubulorenal damage; almost all patients experience severe nausea and vomiting.…”

Immunoprophylaxis with Calmette-Guérin Bacillus in Recurrent Superficial Bladder Tumors

“…However, in travesical chemoprophylaxis is of current use to avoid or delay recurrences after TUR. Thiotepa, adriamycin, epodyl, mitomycin C and cisplatinum are drugs commonly employed [1][2][3][4][5].…”